Design of Cyclic Vinyl Sulfones as WRN Covalent Inhibitors from Noncovalent Binders环状乙烯基磺酸酯作为WRN共价抑制剂的非共价结合物设计Journal of Medicinal ChemistryIF6.82026-04-290PRE
Recent advances in the design of RAR α and RAR β agonists as orally bioavailable drugs. A reviewBIOORGANIC & MEDICINAL CHEMISTRYIF32020-10-0117OAAI
Mycobacterium tuberculosis Decaprenylphosphoryl-β-D-ribose Oxidase Inhibitors: Expeditious Reconstruction of Suboptimal Hits into a Series with Potent in Vivo ActivityJOURNAL OF MEDICINAL CHEMISTRYIF6.82020-01-1024OAAI
Identification and Optimization of Novel Small c-Abl Kinase Activators Using Fragment and HTS MethodologiesJOURNAL OF MEDICINAL CHEMISTRYIF6.82019-01-2819OAAI
Design and synthesis of a potent, highly selective, orally bioavailable, retinoic acid receptor alpha agonistBIOORGANIC & MEDICINAL CHEMISTRYIF32018-02-0110OAAI
Fluparoxan: A Comprehensive Review of its Discovery, Adrenergic and CNS Activity and Treatment of Cognitive Dysfunction in Central Neurodegenerative DiseasesMINI-REVIEWS IN MEDICINAL CHEMISTRYIF3.32017-04-113PRE
Structurally Diverse Mitochondrial Branched Chain Aminotransferase (BCATm) Leads with Varying Binding Modes Identified by Fragment ScreeningJOURNAL OF MEDICINAL CHEMISTRYIF6.82016-03-1625OAAI
The Discovery of in Vivo Active Mitochondrial Branched-Chain Aminotransferase (BCATm) Inhibitors by Hybridizing Fragment and HTS HitsJOURNAL OF MEDICINAL CHEMISTRYIF6.82015-07-0231PREAI
2,5-diketopiperazines in food and beverages: Taste and bioactivityCRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITIONIF8.82015-01-2872PREAI
Structure-guided optimization of small molecule c-Abl activatorsJOURNAL OF COMPUTER-AIDED MOLECULAR DESIGNIF3.12014-02-275OAAI
Pyridyl-2,5-Diketopiperazines as Potent, Selective, and Orally Bioavailable Oxytocin Antagonists: Synthesis, Pharmacokinetics, and In Vivo PotencyJOURNAL OF MEDICINAL CHEMISTRYIF6.82012-01-1247PREAI
The Design of Orally Bioavailable 2, 5-diketopiperazine Oxytocin Antagonists: From Concept to Clinical Candidate for Premature LaborMEDICINAL RESEARCH REVIEWSIF11.62011-06-2439PREAI
Factor Xa inhibitors:: S1 binding interactions of a series of N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}sulfonamidesJOURNAL OF MEDICINAL CHEMISTRYIF6.82007-03-0651PREAI
2,5-Diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 3. Synthesis, pharmacokinetics, and in vivo potencyJOURNAL OF MEDICINAL CHEMISTRYIF6.82006-06-2146PREAI
2,5-Diketopiperazines as potent, selective, and orally bioavailable oxytocin antagonists. 2. Synthesis, chirality, and pharmacokineticsJOURNAL OF MEDICINAL CHEMISTRYIF6.82005-10-0852PREAI
Design of translactam HCMV protease inhibitors as potent antiviralsMEDICINAL RESEARCH REVIEWSIF11.62005-03-2330PREAI
Design and synthesis of pyrrolidine-5,5′-trans-lactams (5-oxo-hexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease.: 4.: Antiviral activity and plasma stabilityJOURNAL OF MEDICINAL CHEMISTRYIF6.82003-09-1777PREAI
Design and synthesis of pyrrolidine-5,5-trans-lactams (5-oxohexahydropyrrolo[3,2-b]pyrroles) as novel mechanism-based inhibitors of human cytomegalovirus protease.: 2.: Potency and chiralityJOURNAL OF MEDICINAL CHEMISTRYIF6.82001-12-0573PREAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向